The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
The European Commission on Monday approved AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as a tissue-agnostic treatment for previously treated patients with unresectable or ...
The firm also said it completed enrollment in the Phase III 4FRONT-2 clinical trial of 4D-150 in wet AMD ahead of schedule.
The company is planning to test its oral immunotherapy in over 800 patients with resectable and unresectable tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results